Oramed Completes Patient Enrollment in Phase 2 Oral Insulin NASH Trial

– Topline results expected H2 2022 – ORMD-0801 is the first oral insulin to be evaluated as a treatment for NASH – Currently no FDA approved therapy exists for NASH NEW YORK , March 16, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP), (TASE: ORMP), a clinical-stage pharmaceutical